Key Metrics
12.4
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
5 - 10
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
235
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
0.85
5-Year SI
5-year SI
- 0.86 2-year SI
- 0.84 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Oncology
SJR
- Q1 Oncology
- Q1 Cancer Research
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
2.67
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
3 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
69%
4 to 6 months
30%
7 to 9 months
2%
Above 9 months
0%
Did you find this useful?
Thank you for your feedback.
Topics Covered
- Cancer
- Overall survival
- Lung cancer
- Drug discovery
- Lymph node
- Progression-free survival
- Breast cancer
- Immunotherapy
- Hysterectomy
- Germline
- Immune checkpoint
- Cohort study
- Melanoma
- Neuroendocrine tumors
- Extracellular vesicles
- Toxicity
- Machine learning
- Chemotherapy
- Assay
- Lymphoma
Journal Specifications
| Overview | |
| Publisher | ELSEVIER SCI LTD |
| Language | English |
| Frequency | Semi-monthly |
| General Details | |
| Language | English |
| Frequency | Semi-monthly |
| Publication Start Year | 1965 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in European Journal of Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
SHared decision-making supported by OUTcome information regarding surveillance after curative treatment for Breast Cancer: Results of the SHOUT-BC study
- 1 Dec 24
- European Journal of Cancer
-
Full paper
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1%–49%): TOPGAN2023-01
- 1 Dec 24
- European Journal of Cancer
-
Full paper
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study
- 1 Dec 24
- European Journal of Cancer
-
Full paper
PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohort
- 1 Dec 24
- European Journal of Cancer
-
Full paper
Epidemiology of men with synchronous metastatic prostate cancer diagnosis – A nationwide 26-year temporal analysis
- 1 Dec 24
- European Journal of Cancer
-
Full paper
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
- 1 Dec 24
- European Journal of Cancer
Scite analysis
Powered by scite_
40k articles received 519.3k citations see all
- 21,833 Supporting
- 477,106 Mentioning
- 3,877 Contrasting
Editorial notices
- 5 Retractions
- 4 Withdrawals
- 0 Corrections
- 74 Errata
- 0 Expression of Concern
FAQs
How long has European Journal of Cancer been actively publishing?
European Journal of Cancer has been in operation since 1965 till date.
What is the publishing frequency of European Journal of Cancer ?
European Journal of Cancer published with a Semi-monthly frequency.
How many articles did European Journal of Cancer publish last years ?
In 2023, European Journal of Cancer published 501 articles.
What is the eISSN & pISSN for European Journal of Cancer ?
For European Journal of Cancer,eISSN is 1879-0852 and pISSN is0959-8049.
What is Citescore for European Journal of Cancer ?
Citescore for European Journal of Cancer is 12.4.
What is H index for European Journal of Cancer ?
H index for European Journal of Cancer is 235.
What is SNIP score for European Journal of Cancer ?
SNIP score for European Journal of Cancer is 2.67.
What is the SJR for European Journal of Cancer ?
SJR for European Journal of Cancer is Q1.
Who is the publisher of European Journal of Cancer ?
ELSEVIER SCI LTD is the publisher of European Journal of Cancer.